Treatment of Patients with ALK-positive Non-small Cell Lung Cancer and Brain Metastases
- VernacularTitle:ALK阳性非小细胞肺癌脑转移患者的治疗
- Author:
LV JIALIN
1
;
ZHANG QUAN
;
QIN NA
;
YANG XINJIE
;
ZHANG XINYONG
;
WU YUHUA
;
LI XI
;
ZHANG HUI
;
WANG JINGHUI
;
ZHANG SHUCAI
Author Information
1. 101149 北京，首都医科大学附属北京胸科医院肿瘤内科，北京市结核病胸部肿瘤研究所
- Keywords:
Lung neoplasms;
ALK;
Brain metastases
- From:
Chinese Journal of Lung Cancer
2016;19(8):519-524
- CountryChina
- Language:Chinese
-
Abstract:
Background and objectiveAnaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) is an important subtype of lung cancer. hTe standard modality of ALK-positive NSCLC with brain metastases re-mains uncertain.MethodsWe collected data on clinical characteristics and treatment of patients with ALK-positive NSCLC and brain metastases between March 2013 and March 2016 and retrospectively analyzed patient outcomes.Results In 84 ALK-positive patients with advanced NSCLC, 22 (26.2%) had brain metastases during the initial diagnosis of lung cancer, among which 3 patients with EGFR mutation were excluded, and 19 patients were analyzed. Median intracranial progression-free survival (PFS) was 12.0 months. PFS for patients who received first-line local brain therapy (P=0.021) and crizotinib therapy (P=0.030) was superior to PFS for patients without such therapies. PFS for patients who received ifrst-line crizotinib combined with local brain therapy was 27.0 months and only 4.2 months for those who received crizotinib alone.Conclusion First-line crizotinib therapy combined with local brain treatment can improve intracranial PFS for ALK-positive NSCLC with brain metastases. hTis ifnding should be conifrmed further through multicenter, prospective clinical trials with large sample size.
